Purpose: The long-term experience of linked semicon-strained total elbow arthroplasty was investigated as a salvage procedure for patients with distal humerus non-union not amenable to internal fixation.

Method: Ninety-two consecutive total elbow arthroplasties performed for the treatment of a distal humeral nonunion were reviewed at an average follow-up of 6.5 years (range, 0.5 to 20.3 years). There were twenty-two men and sixty-nine women with an average age of sixtyfive years (range, twenty-two to eighty-four years) at the time of elbow replacement. Seventy-six elbows (83 per cent) had undergone prior surgery, with an average of two previous operations (range, one to ten). Five elbows had had at least one prior operation due to infection.

Results: Seventy-nine per cent of the patients had no pain or mild pain at latest follow-up compared with moderate or severe pain in 86 percent prior to surgery. Mean extension was improved from thirty-seven to twenty-two degrees and mean flexion from 106 to 135 degrees. Joint stability was restored in all patients, including nine with a grossly flail elbow. Complications included aseptic loosening in sixteen (four with periprosthetic fractures), component fracture in five, deep infection in five (three with previous infection), and bushing wear in one patient. At most recent follow-up, 85 per cent of the patients were satisfied with their outcome. Survivorship for not requiring removal or revision for any cause was 95.7 per cent at two years, 82.1 per cent at five years, 65.3 per cent at ten and fifteen years. Factors that increased the risk of implant failure were patient age less than sixty-five, two or more prior surgeries, and history of previous infection.

Conclusion: Linked semiconstrained total elbow arthroplasty provides a reliable salvage procedure to provide pain relief and restoration of motion and function in patients with distal humerus nonunion not amenable to internal fixation. Risk factors for failure include younger patients, multiple previous surgeries, and history of infection.

Purpose: We conducted a retrospective review to evaluate outcomes, complications and implant survival after shoulder reconstruction for bone neoplasm using anatomic shoulder prostheses.

Method: Thirty-four anatomic shoulder prostheses were reviewed at an average follow-up of 51 (range, 6 to 143) months. The mean age at the time of surgery was 47 (range, 15 to 74) years. Twenty-five patients (74%) had reconstruction with an allograft-prosthetic composite (APC). The average amount of humerus resected in patients with an APC was 13 cm (range, 5 to 36 cm).

Results: At most recent follow-up, 82% of patients had no pain (11), slight pain (12) or moderate pain with strenuous activities (5). Twenty-eight patients (82%) were subjectively satisfied despite only 29% being satisfactory according to Neer rating. Sixteen complications occurred in 13 patients, including instability (5), host/graft non-union (3), aseptic loosening (3), arthrofibrosis (1), tumor recurrence (2) and superficial infection (1). Host/graft nonunion occurred in 3/9 patients with an APC using press-fit or plate fixation for distal humeral fixation and 0/16 shoulders with cemented distal humeral fixation (p=0.02). Three implants required revision for aseptic loosening (1), host/graft nonunion (1) and instability (1). Kaplan-Meier survivorship at 10 years was 88% for implant revision and 80% for mechanical failure.

Conclusion: Reconstruction of the proximal humerus using an anatomic prosthesis after resection of bone neoplasms is associated with a low rate of mechanical failure but a moderate rate of shoulder instability. Cement fixation into the native distal humerus should be considered when reconstruction using an APC is required.

Purpose: Loosening of the humeral component is rarely a cause for revision shoulder surgery. Most long-term series are not large enough to stratify the many risk factors that might influence the survivorship of humeral component designs. The purpose of this study was to determine long-term survivorship of the Neer and Cofield humeral components and to define the risk factors associated with humeral component removal or revision.

Method: 1584 primary Neer and Cofield shoulder arthroplasties (1423 patients) were performed at our institution from 1984 to 2004. There were 619 men (694 shoulders) and 804 women (890 shoulders), with a mean age at arthroplasty of 65.6 years (range, 16–94 years). Kaplan-Meier survivorship analysis was used to determine the effect of etiology of the disease, gender, age, surgery type (hemi versus total), fixation type (cemented versus noncemented), and the humeral component type (Neer II, Cofield I or II) on the estimated survival free of humeral component revision or removal.

Results: There were 108 revisions and 17 removals of the humeral component. The overall rate of removal or revision of the humeral component was 7.9% with an average followup of 8.1 years. The rates of survivorship free of revision or removal of the humeral component for any reason was 94.8% at 5 years, 92% at 10 years, 86.7% at 15 years and 82.8% at 20 years. Seventy-one of 632 shoulders (11.2%) in patients younger than 65 years required humeral component revision or removal, whereas only 54 of 952 shoulders (5.7%) in patients 65 years and older required humeral component revision or removal (Odds ratio=2.1; 95% confidence interval, 1.5–3, p=0.001). Patients with posttraumatic arthritis had a higher risk of needing revision or removal of the humeral component (Odds ratio=2.1, 95% confidence interval 1.3–3.3) compared to osteoarthritis. Eighty-four of 526 shoulders (16.0%) with metal-back glenoid components required humeral component revision or removal, whereas only 41 of 1058 shoulders (3.9%) with non metal-backed glenoid components required humeral component revision or removal (Odds ratio=4.7; 95% confidence interval, 3.2–7, p=0.001).

Conclusion: Younger age, replacement due to post-traumatic arthritis and presence of a metal-backed glenoid increased the likelihood of humeral component failure. Similar short-term survival can be achieved with Cofield II and Neer II humeral components.